Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
The group eyes a broader use than Immunocore’s Kimmtrak.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.